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Saibal Kar, MD, Rahul Sharma, MDSEE PAGE 1809T ranscatheter aortic valve replacement(TAVR) is an established treatment for pa-tients with severe aortic stenosis (AS)
deemed to be at high risk for surgery (1,2). The ﬁrst-
generation balloon-expandable SAPIEN (Edwards
Lifesciences, Irvine, California) transcatheter heart
valve (THV) was the ﬁrst device to be approved by
the U.S. Food and Drug Administration (FDA) for
inoperable, and subsequently, high-risk patients
with AS. Limitations of the ﬁrst-generation SAPIEN
device included access-site related vascular compli-
cations, inconsistent positioning, paravalvular aortic
valve regurgitation, and periprocedural strokes. Sub-
sequent iterations of the SAPIEN THV included mod-
iﬁcations in device design translating to improved
performance and clinical outcomes. The Edwards-
SAPIEN 3 (S3) is the ﬁfth-generation balloon-expand-
able THV device. The valve and delivery system
contain a number of improvements designed to
reduce the risk of access site vascular injury, facilitate
consistent and accurate positioning, and mitigate
paravalvular regurgitation. The valve comprises a co-
balt chromium stent, bovine pericardial leaﬂets, and
an inner and outer polyethylene terephthalate seal-
ing cuff. The unique cell design of the frame allows
an ultra-low delivery proﬁle while maintaining radial
strength for circularity. The outer sealing skirt acts to
minimize paravalvular regurgitation. The delivery
system allows distal ﬂex to help cross in challenging
anatomies and control coaxiality, and has a handle
that reﬂects degree of articulation, to ensure precise
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contents of this paper to disclose.and 29 mm), enabling treatment of a greater range
of native aortic annular sizes. All valves aside from
the 29-mm device are compatible with a 14-F sheath.
The low proﬁle characteristics of the sheath and cath-
eter allow passage through femoral arteries as small
as 5.5 mm in diameter with signiﬁcantly fewer
vascular complications. Previously, patients with
small-caliber femoral vessels were subject to alter-
native access, such as transaortic or transapical
approaches, with worse clinical outcomes compared
with those undergoing the transfemoral approach (3).
The SAPIEN 3 THV received approval for high-risk
patients with AS in Europe in January 2014 (CE
Mark) and in the United States in June 2015 (FDA).
The CE Mark was based on results from 1 non-
randomized study (4). The excellent clinical out-
comes observed with SAPIEN 3 were further
conﬁrmed by the results of subsequent clinical
studies, including 1 study assessing intermediate-risk
patients (5). FDA approval was based on the results of
the PARTNER (Placement of AoRTic TraNscathetER
Valve) II S3 trial, the largest TAVR trial to date (6). The
trial comprised 2 single-arm, multicenter, non-
randomized studies assessing outcomes in high-risk/
inoperable and intermediate-risk/operable patients
compared with outcomes in the historical SAPIEN and
SAPIEN XT groups. Excellent clinical outcomes were
seen in both groups at 30 days and at 1 year. Longer-
term follow-up is awaited.In this issue of JACC: Cardiovascular Interventions,
Husser et al. (7) report 30-day outcomes of 250 pa-
tients treated with the SAPIEN 3 valve at a single
center. The authors should be congratulated on the
sample size of their study, meticulous recording of
clinical data in accordance with the updated Valve
Academic Research Consortium 2 criteria, and excel-
lent overall clinical outcomes. This study population
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1818was similar to those in previously published studies,
with advanced age, multiple comorbidities, and an
intermediate risk proﬁle based on Society of Thoracic
Surgeons risk score. All procedures were performed
via a transfemoral approach using a 23-mm valve in
the majority of cases, with a high overall device suc-
cess rate (97.4%). A total of 5 (2%) patients were left
with grade 3 aortic regurgitation, with one patient
requiring a second valve implantation to treat severe
paravalvular regurgitation.
There were no in-hospital deaths, and only 1 death
within 30 days. There were 4 cases of major disabling
stroke (1.6%), with an overall stroke rate of 3.2% at 30
days. Major vascular complications occurred in 3.6%,
and the rate of new pacemaker implantation was
15.2%. Although these ﬁndings are generally consis-
tent with previously published SAPIEN 3 experience,
the stroke and pacemaker rates appear to be slightly
higher in this real-world series.
The slightly elevated stroke rate in this series may
be attributable to 2 causes. First, the higher than
usual rate of post-dilation in this study compared
with previous studies may have contributed to
embolic events. Second, following the procedure,
there may have been thrombus formation on the
valve with subsequent embolization. The antith-
rombotic therapy administered in this series was not
discussed. It is possible that the routine use of
cerebral protection devices in conjunction with
better post-procedure antithrombotic therapy might
help in further reduction of neurological events.
The results of ongoing clinical trials to explore the
effect of cerebral protection devices and the optimal
antiplatelet or anticoagulation regimen are eagerly
anticipated.
Despite advances in THV technology, the require-
ment for permanent pacemakers remains an issue. In
this series, the slightly elevated rate of permanent
pacemaker implants may have been related to acombination of relative oversizing, increased depth of
implantation, and the use of post-dilation in over
one-third of cases.
Despite enrolling a relatively large sample size with
excellent overall clinical outcomes, this study does
have certain limitations. Although this series reﬂects a
real-world application of the SAPIEN 3 device, outside
of the rigorous constraints of a clinical trial, the
absence of independent adjudication of data may lead
to under-reporting of clinical events. A further limita-
tion of a single-center study, particularly at an expe-
rienced center, is the inability to reproduce and
extrapolate the degree of clinical success to a larger
population at other institutions.
There have been major advances in THV therapy
since the inception of TAVR. The emergence of new
devices coupled with the evolution of existing
technologies has helped catalyze the rapid progres-
sion of the THV ﬁeld. Once limited to large, tertiary
centers participating in multicenter clinical trials,
TAVR is now available in over 60 countries to cen-
ters with appropriate infrastructure that can
demonstrate adequate procedural experience. The
SAPIEN 3 THV, with its excellent safety and efﬁcacy
proﬁle, particularly low mortality, low stroke, and
minimal paravalvular leak, has set a new benchmark
against which all other THV devices should be
compared. Further advances in device technology
and delivery methods will no doubt further reduce
the incidence of stroke and pacemaker requirement.
It is only a matter of time before TAVR will be the
standard therapy for aortic stenosis, irrespective of a
patient’s risk proﬁle.
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